Journal: Cancer discovery
A large retrospective analysis compared people prescribed GLP-1 receptor agonists with those taking aspirin and found a 36% lower risk of developing colorectal cancer in the GLP-1 group.
While the absolute risk reduction for an individual patient was small, the authors highlight that the widespread use of GLP-1 drugs means that, at a population level, thousands of colorectal cancer cases might potentially be prevented.
The study is observational, so it cannot prove causation, but it raises the possibility that GLP-1–based therapies may have incidental cancer-preventive effects beyond their primary indications.
- 36% lower colorectal cancer risk in people taking GLP-1 receptor agonists compared with aspirin.
- Small absolute risk reduction per person, but potentially large impact at the population level.
- Observational study, so it cannot prove causation but suggests possible incidental cancer-preventive effects of GLP-1 therapies.